Decheng Capital LLC: 13F holdings
CIK 20108502026Q2
| Positions | 14 |
|---|
| Reported value | $731.7m |
|---|
| Filed | 2026-08-14 |
|---|
Change since last quarter
| Positions | 14 (+0 vs prior quarter) |
|---|
| Reported value | $731.7m (+10.7%) |
|---|
Top 10 holdings
| Security | Shares | Value | Weight |
|---|
| CGON CG ONCOLOGY INC | 6,371,669 | $452.7m | 61.9% |
| NUVB Nuvation Bio Inc. | 25,954,439 | $147.4m | 20.1% |
| AARDVARK THERAPEUTICS INC | 3,917,299 | $22.6m | 3.1% |
| ACRS Aclaris Therapeutics, Inc. | 4,041,736 | $21.4m | 2.9% |
| UPB Upstream Bio Inc. | 2,724,868 | $18.9m | 2.6% |
| RCUS Arcus Biosciences, Inc | 464,779 | $14.3m | 2.0% |
| Equillium Inc. | 4,447,308 | $14.2m | 1.9% |
| RVMD REVOLUTION MEDICINES INC(NSM) | 52,667 | $9.9m | 1.3% |
| Lyell Immunopharma, Inc. | 692,050 | $9.7m | 1.3% |
| BeyondSpring Inc. | 3,800,702 | $6.7m | 0.9% |
Get the full book
import finzdata as yf
yf.Client().manager_holdings(cik="2010850")
Every position, quarter by quarter since 2013, with adds, trims and exits, on the look-back bundles.
Get a free API keySee history bundlesDownload free samples